糖尿病のない米国の成人の血清インスリンと高インスリン血症の平均傾向 (1999年−2018年)
Tammie M Johnson1, James R Churilla2
1Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Tallahassee, FL, United States.
Journal of diabetes and its complications
|September 6, 2025
まとめ
禁食インスリン濃度と高インスリン血症の罹患率は20年以上にわたって糖尿病のない米国成人の間で著しく増加しています. この傾向は2型糖尿病の予防に 懸念が高まっていることを示しています
科学分野:
- 内分泌学
- 代謝 健康
- 公衆衛生
背景:
- 超インスリン血症は,異常なインスリン濃度で特徴づけられる状態です.
- インスリン抵抗性や2型糖尿病のリスクが増加します.
- インスリン濃度の傾向を理解することは,糖尿病予防を目的とした公衆衛生戦略にとって極めて重要です.
研究 の 目的:
- 平均血清インスリン濃度と高インスリン血症の流行傾向を分析する.
- 糖尿病と診断されていない米国人の傾向を調査する.
- 1999年から2018年までの20年間のデータを調査する.
主な方法:
- 1999年から2018年の国家健康栄養調査 (NHANES) のデータを活用した.
- 20歳以上で妊娠していない米国人14,150人を対象に,糖尿病の既往歴と特定のグルコース基準はありませんでした.
- トレンドを評価するために,5つの4年間の間隔に集約されたデータ.
主要な成果:
- 平均断食インスリン濃度 (APC) は,年間5. 64%から7. 65%に増加した.
- 高インスリン血症の罹患率は,年間19. 4%から22. 3%に大幅に増加した.
- この2つの傾向はジェンダーサブグループ全体で一貫して顕著でした.
結論:
- 糖尿病のない米国の成人は,平均断食インスリンと高インスリン血症の20年間の上昇傾向を示しています.
- これらの発見は,代謝機能障害の増加を強調しています.
- インスリントレンドのモニタリングは2型糖尿病の予防のための重要な洞察を提供します.
さらに関連する動画
関連する概念動画
Insulin: Dosing Regimen and Adverse Effects
252
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
252
Diabetes: Symptoms, Diagnosis, and Complications
684
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
684
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Insulin Formulations: Types and Delivery
269
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
269
Diabetes Mellitus: Overview and Type I Subtype
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K
Hypoglycemia and Glucagon
334
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334


